MYDNA

ጞ § 🌢 🗙 🏷 🖈

PERSONALISED WELLNESS

AN INTRODUCTION AND OVERVIEW OF myDNA'S SUITE OF POWERFUL PERSONALISED HEALTH SOLUTIONS



JUNE, 2020

WE ARE LIVING IN AN ERA OF PERSONALISATION

Businesses offering a personalized experience are the benchmark now. People these days want something that is relevant to them and not just a one-size-fits-all approach.

Personalization can no longer be considered a luxury or an add-on. It's a big part of the modern world and its expanding.



of businesses are investing in personalization and 51% of marketers say that personalization is their number 1 priority



MYDNA



of consumers bought items they did not intend to due to personalized recommendation





of consumers say they will likely repeat a purchase after a personalized shopping experience




MYDNA

NUTRITION + FITNESS

SUPERCHARGE YOUR DIET AND TRAINING ROUTINES WITH DNA-POWERED INSIGHTS





MYDNA NUTRITION + FITNESS

With people becoming more and more conscious of healthy living and the health and fitness sector littered with generic options, its harder to find a plan that will work for you.

In society today, the advice and recommendations are tailored to the national average. Poor diet planning, lack of knowledge and unrealistic expectations push people away from achieving their goals.

Enter myDNA Nutrition and Fitness, your one stop shop for all your diet and exercise needs designed specifically to your DNA. You can argue with generic advice, but you cant argue with your DNA.

Benefits of myDNA Nutrition and Fitness:

- Science-based DNA Nutrition plan tailored to your unique body, with every calorie and macronutrient calculated to achieve your goal
- Customised DNA Fitness plan designed to get the results you want, where you want, with home and gym workout options
- Simple at-home-cheek-swab revealing genetic insights to power your plans – fat burning, fat storage, power, endurance, stamina, injury risk and more
- Ongoing self-discovery and support with regular new DNA Insights
- Goal tracking, shopping list and inspirational articles



1 in 5

MYDNA

Australians are obese



Of diets fail due to:

- Poor dietary planning
- Lack of Health literacy
- Unrealistic expectations



Of gym goers in Australia don't utilize their membership. This is due to lack of knowledge, time and demotivation . (Est out of 5,000,000)

INSIGHTS ARE GROUPED INTO 3 CATEGORIES

CORE FOCUS

These are aspects of your health you need to take action on to ensure you are maintaining optimal wellness.

PAY ATTENTION

You may need to work with your genes to optimise these aspects of your health.

TYPICAL

No specific actions required.

DISCOVER 4 KEY 7 GENES FITNESS INSIGHTS... 7 MARKERS

POWER VS ENDURANCE



INJURY RISK

STAMINA



RECOVERY

DISCOVER 7 KEY NUTRITION INSIGHTS... 7 GENES 9 MARKERS FAT BURNING + WEIGHT

FATTY ACID PROCESSING

APPETITE + WEIGHT

WEIGHT RETENTION

FIBRE

PROCESSING OF DIETARY FATS



•

FAT BURNING + WEIGHT

myDNA NUTRITION AND FITNESS

MYDNA



OVER 32,000,000 PERSONALISED MEAL PLAN COMBINATIONS

OVER 50,000 PERSONALISED FITNESS PLANS



Everyone is unique, so why trust a generic diet or workout?

By following a personalised myDNA plan, you can achieve your goals faster with the confidence that your nutrition and fitness is tailored specifically to your unique genetic make up.

myDNA

PERSONALISED VITAMINS

FOCUS ON YOUR IMMUNITY AND WELLNESS WITH PERSONALISED VITAMIN INSIGHTS



MYDNA VITAMINS

Consumers these days are overwhelmed by the sheer number of vitamins and supplements that are on offer. It can be difficult to determine what is a marketing spin verses what is required for optimum health.

In the Vitamins test we use 15 genetic markers that provide information regarding 9 micronutrients. This helps choose the right fuel for your body, while giving you an easy-to-action food guide to maintain it.

PERSONALISED INSIGHTS


- Take the guesswork out of choosing multivitamins. myDNA lets you know exactly which vitamins your body needs, saving you time and money
- Avoid taking unnecessary, ineffective, or dangerous supplements with clear, concise, and easy to action insights

DNA-POWERED VITAMIN FOOD GUIDE

- Turn your insights into action with a personalised Vitamin Food Guide
- Learn which foods you personally need to focus on, helping you make simple tweaks to your diet

BOOST YOUR IMMUNITY

- Studies show that low levels of Calcium, Iron, Folate and Vitamins A, C, D, B6 & B12 can weaken the immune system, making you more susceptible to infections
- Personalised vitamin insights to help you stay on top of and strengthen your immune system



69%

Of Australians take vitamins every week.

71%

Of Australians are taking vitamins without professional advice.

11%

Of Australians spend more than \$100 a month on vitamins.

MyDNA[®]

myDNA

DISCOVER 9 KEY VITAMIN INSIGHTS...

9 GENES 15 MARKERS

... GROUPED INTO 3 CATEGORIES

CORE FOCUS

These are aspects of your health you need to take action on to ensure you are maintaining optimal wellness.

PAY ATTENTION

You may need to work with your genes to optimise these aspects of your health.

TYPICAL

No specific actions required.





SUPERCHARGE YOUR VITAMIN INTAKE

myDNA

PERSONALISED INSIGHTS

- Take the guesswork out of choosing multivitamins. myDNA lets you know exactly which vitamins your body needs, saving you time and money
- Avoid taking unnecessary, ineffective, or dangerous supplements with clear, concise, and easy to action insights

DNA-POWERED VITAMIN FOOD GUIDE

- Turn your insights into action with a personalised Vitamin Food Guide
- Learn which foods you personally need to focus on, helping you make simple tweaks to your diet

BOOST YOUR IMMUNITY

- Studies show that low levels of Calcium, Iron, Folate and Vitamins A, C, D, B6 & B12 can weaken the immune system, making you more susceptible to infections
- Personalised vitamin insights to help you stay on top of and strengthen your immune system



myDNA

MEDICATIONS TESTING

STREAMLINING PRESCRIPTION FOR PAIN + MENTAL HEALTH WITH PHARMACOGENOMICS

The myDNA Medication tests use pharmacogenomics to identify variations in a number of genes that influence responses to medications and healthcare treatments.

We offer a multiple medications test, which covers multiple medication categories (currently in excess of over 80 medications). However, if a specific category is more suitable, we also offer single category medication reports.



THE POWER OF PHARMACOGENOMICS

FAST-TRACK HEALTHCARE GOALS AND **ENABLE PERSONALISATION FOR EVERY** PATIENT WITH PHARMACOGENOMIC **GUIDED PRESCRIBING.**

- Reduce the risk of side effects and maximise effectiveness by understanding the role your genetics play in processing certain medication.
- myDNA can help alleviate the trial-and-error aspect of finding the right dose and ensure patients are taking both safe and effective doses.
- Prescription recommendations for your doctor, based on your specific results. Your ٠ insights are delivered directly to your healthcare professional for them to review your results before providing their recommendations.



1 IN 5 AUSTRALIANS

Suffer from persistent pain, making their risk of depression 4x higher than those without pain



1 IN 10 PEOPLE

Respond to the initial treatment with antidepressants



PAIN

MENTAL HEALTH

GASTROINTESTINAL

ONCOLOGY

CARDIOVASCULAR



50% OF PATIENTS

May process certain medications too slowly, increasing their risk of side effects

1 IN 3 PEOPLE

May process certain medications too quickly, increasing their risk of treatment failure

MYDNA

EXAMPLE PGx MENTAL HEALTH REPORT





The following tables outline personalised recommendations for antidepressants.

NOTE: These tables do not account for the effect of any inhibitors or inducers. The table is not an all-inclusive list of antidepressants.

MEDICATIONS WITH MAJOR PRESCRIBING CONSIDERATIONS

MEDICATION	INTERPRETATION	RECOMMENDATION	atine with this ip of changes patient		
 Citalopram (SSRI) 	CYP2C19 - Ultrarpid metaboliser: Increased metabolism of citalopram by CYP2C19 and reduced drug exposure are predicted. This may increase the likelihood of therapeutic failure.	CPIC guidelines' provide a moderate recommendation to consider an alternative antidepressant not predominantly metabolised by CYP2C19. If the clinical response has been adequate, a change to therapy may not be required.	is not clear. Holiser Haboliser (with Haby a number 22D6 and hotype mand the	No genotype-guided dosing recommendation available. Monit reduced clinical response, especi smokers.	
Escitalopram (SSRI)	CYP2C19 - Ultrarapid metaboliser: Increased metabolism of escitalopram and reduced drug exposure are predicted. This may increase the likelihood of therapeutic failure.	CPIC guidelines ¹ provide a moderate recommendation to consider an alternative antidepressant not predominantly metabolised by CYP2C19. If the clinical response has	ts increased plasma ence of smoking.		
	ikeinood of therapeutic failure.	been adequate, a change to therapy may not be required.	ataboliser: CYP2C19 and ations are nificance of	No genotype-guided dosing recommendation available. Be ale reduced clinical response.	
Amitriptyline (TCA)	CYP2D6 - Normal metaboliser CYP2C19 - Ultrarapid metaboliser: Amitriptyline is metabolised by	For use at higher doses such as in the treatment of depression, CPIC ² provides an optional recommendation to consider	reduced ad.		
	CYP2C19 into an active metabolite, which is further metabolised by CYP2D6 into an inactive metabolite. Increased metabolism and reduced plasma concentrations of amitripyline are predicted. There may be an increased risk of thereputic failure with amitripyline. Normal metabolism of the active metabolite is predicted.	an alternative drug not metabolized by CYP2C19, such as nortirybline. If amitripyline is required, consider therapeutic drug monitoring to guide dose adjustments. For use at lower doses such as in treatment of neuropathic pain, if currently well tolerated and clinical response has been adequate, a change to therapy may not be required. Notriptyline may be more suitable from a metabolism perspective.	oliser aboliser (with by both h CYP1A2 le. Normal CYP2D6 and CYP1A2 in ne inducers predicted. The b be reduced trations and cal response.	No genotype-guided dosing recommendation available. Be ale an inadequate response, especiall smokers.	
		a metabolism perspective.	cal response.		
	concentrations of amitripyline are predicted. There may be an increased risk of therapeutic failure with amitripyline. Normal metabolism of the active metabolite is predicted.	dose adjustments. For use at lower doses such as in treatment of neuropathrogan, if currenty well tolerated and clinical response has been adequate, a change to therapy may not be required. Northpyline may be more suitable from	h, CYP1A2 ile. Normal CYP1A2 in predicted. The predicted. The itrations and		
	Amitrippyine is metabolised by CYP2C19 into an active metabolite, which is further metabolised by CYP2D6 into an inactive metabolite. Increased metabolism and reduced plasma	an optional recommendation to consider an alternative drug not metabolized by CPPC19, such as nortriptyline. If amitriptyline is required, consider therapeutic drug monitoring to guide	xoliser taboliser (with I by both	No genotype-guided dosing recommendation available. Be ale an inadequate response, especiall smokers.	
	CYP2C19 - Ultrarapid metaboliser:				

BING CO	INSIDERATIONS					_	
	RECOMMENDATION				5 🗸 🔺 Your Profile 🗸 🎽		
iser (with	No genotype-guided dosing					Drug Name	Trade Name
	recommendation available. Monitor for a reduced clinical effect.					Amitriptyline	Endep
abolism and red ons are posure to bacco of argrilled ns (e.g. monstrated a ma ne with this of changes batient not clear.	reduced clinical effect.	IS	CATEGORIES		REPORTS	Clomipramine	Anafranil, Placil
						Dothiepin	Dothep, Prothiaden
						Doxepin	Deptran
		IHME	DICATIONS	Duloxetine^	Cymbalta		
			ADHD Medications	Fluoxetine	Prozac, Lovan, Zactin		
	No genotype-guided dosing recommendation available. Monitor for reduced clinical response, especially in	à				Fluvoximine [^]	Luvox
		lications	MINOR IMPACT			Imipramine	Tofranil, Tolerade
						Mirtazapine^	Avanza, Mirtazon Axit
r (with			atomoxetine			Nortriptyline	Allegron
umber d	smokers.					Paroxetine	Aropax, Paxtine, Extine
		dications	Antidepressants - Other			Trimipramine	Surmontil
and the icreased						Venlafaxine	Efexor
		ications	MINOR IMPACT	MINOR IMPACT			Brintellix
e of oking.							
YP2C19 and ons are ficance of duced liser poliser (with	No genotype-guided dosing recommendation available. Be alert to a reduced clinical response. No genotype-guided dosing recommendation available. Be alert to an inadequate response, especially in smokers.		Mianserin	Moclobemide	Vortioxetine		
		ions				Drug Name	Trade Name
		10113	Antidepressants - Selec	Amitriptyline	Endep		
			MAJOR IMPACT	Citalopram	Cipramil, Celapram		
				Clomipramine	Anafranil, Placil		
						Dothiepin	Dothep, Prothiaden
	anokora.		citalopram	escitalopram	paroxetine	Doxepin	Deptran
						Escitalopram	Lexapro, Esipram
			MINOR IMPACT	MINOR IMPACT			Tofranil, Tolerade
						Moclobemide	Aurorix, Amira
			Fluoxetine	sertraline		Sertraline	Zoloft, Xydep, Eleva
						Trimipramine	Surmontil
					· · · · ·	Trimipramine	Surmontil
ions and response.			Fluoxetine	sertraline		Sertraline	Zoloft, Xydep, Eleva
ed. The luced						Moclobemide	Aurorix, Amira
COLS						Imipramine	Tofranil, Tolerade
formal 2D6 and 1A2 in							Lexapro, Esipram
75				escitalopram		Doxepin	
h	an inadequate response, especially in smokers.					Dothiepin	Dothep, Prothiaden
er (with	No genotype-guided dosing recommendation available. Be alert to					Clomipramine	Anafranil, Placil
	KAJOR MPACT						



COMPANY BACKGROUND

OUR HIGHLY QUALIFIED TEAM AND BROAD SCIENTIFIC PARTNER NETWORK



THE SCIENCE



THE SCIENTIFIC TEAM



ASSOCIATE PROFESSOR LES SHEFFIELD FOUNDING CHIEF MEDICAL DIRECTOR

Clinical geneticist and internationally recognised personalised medicine expert



SAM MOSTAFA ASSOCIATE CLINICAL DIRECTOR Bpharm, AACPA, MPS

KATHRYN VISSER ASSOCIATE GENETIC COUNSELLOR BA BSc.(Hons) MGenCouns



DR NOVITA PUSPASARI SENIOR MOLECULAR GENETICIST Phd, BBiomedSc



MIN YIN GOH CLINICAL PHARMACOLOGIST MBBS, FRACP

MBBS, FRACP

TARA SMITH PROFESSIONAL S Bpharm, GCert

TARA SMITH PROFESSIONAL SERVICES MANAGER Bpharm, GCert

EDI ROGERS ASSOCIATE GENETIC COUNSELLOR BA, Dip Ed, Grad Dip Gen Couns

CARLOTTA PETTI SCIENTIFIC DIRECTOR, NUTRIGENOMICS PhD ANutr BSc (Hons) GradCertPH

ACCREDITATION





Member Global Alliance for Genomics & Health

Medicines & Healthcare products Regulatory Agency





PHARMACOGENOMIC EXPERIENCE



50%

COVER OF GP's IN AUSTRALIA

7000+ DOCTORS USING PGx

10 YEARS PROVIDING PGx SERVICES

GLOBAL NETWORK

AUSTRALIA, NZ, CANADA, UK, THAILAND, SINGAPORE AND MORE

5 MYDNA[™] CLINICAL STUDIES WITH LEADING HOSPITALS

MEDICAL PARTNER NETWORK



